The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis
British Journal of Dermatology2017Vol. 176(4), pp. 928–938
Citations Over TimeTop 1% of 2017 papers
C.E.M. Griffiths, Diamant Thaçi, Sascha Gerdes, Petr Arenberger, Grażyna Pulka, Külli Kingo, Jolanta Węgłowska, on behalf of the EGALITY study group, N HATTEBUHR, Johann Poetzl, Heike Woehling, G. Wuerth, Miguel Afonso Filipe
Abstract
The EGALITY study demonstrated equivalent efficacy and comparable safety and immunogenicity of GP2015 and ETN. The study results provide the final clinical confirmation of biosimilarity and contribute to the totality of the evidence proposing that GP2015 is an etanercept biosimilar.
Related Papers
- → Biosimilar insulins: a E uropean perspective(2014)30 cited
- → Innovation, Patents and Biologics: The Road to Biosimilar Competition: Factors Influencing Investment, Business Decisions and Marketing of Biosimilars(2018)3 cited
- → Biosimilars markets: US and EU compared(2020)3 cited
- → Biosimilar Drugs(2012)3 cited
- → DETERMINING QUALITY REQUIREMENTS AT THE UNIVERSITIES TO IMPROVE THE QUALITY OF EDUCATION(2018)